LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "amyloid cardiomyopathy" as a keyword



Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension.

Sign Up to like & get
recommendations! Published in 2025 at "JAMA cardiology"

DOI: 10.1001/jamacardio.2025.4477

Abstract: This study evaluates the efficacy of acoramidis in transthyretin amyloid cardiomyopathy with wild-type, transthyretin amyloid cardiomyopathy with variant, and variant subgroups (p.Val142Ile and non-p.Val142Ile). read more here.

Keywords: variant; amyloid cardiomyopathy; efficacy acoramidis; wild type ... See more keywords

A simple staging system using biomarkers for wild‐type transthyretin amyloid cardiomyopathy in Japan

Sign Up to like & get
recommendations! Published in 2022 at "ESC Heart Failure"

DOI: 10.1002/ehf2.13847

Abstract: It has been reported that a staging system combining N‐terminal pro‐B‐type natriuretic peptide and high‐sensitivity troponin T (hs‐cTnT) or estimated glomerular filtration rate (eGFR) is useful in patients with wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM). However,… read more here.

Keywords: system; staging system; type transthyretin; amyloid cardiomyopathy ... See more keywords

Suspicion, screening, and diagnosis of wild‐type transthyretin amyloid cardiomyopathy: a systematic literature review

Sign Up to like & get
recommendations! Published in 2022 at "ESC Heart Failure"

DOI: 10.1002/ehf2.13884

Abstract: Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt CM) is a more common disease than previously thought. Awareness of ATTRwt CM and its diagnosis has been challenged by its unspecific and widely distributed clinical manifestations and traditionally invasive… read more here.

Keywords: amyloid cardiomyopathy; type transthyretin; transthyretin amyloid; diagnosis ... See more keywords

Utility of left atrial and ventricular strain for diagnosis of transthyretin amyloid cardiomyopathy in aortic stenosis

Sign Up to like & get
recommendations! Published in 2022 at "ESC Heart Failure"

DOI: 10.1002/ehf2.13909

Abstract: To clarify the usefulness of left atrial (LA) function and left ventricular (LV) function obtained by two‐dimensional (2D) speckle tracking echocardiography to diagnose concomitant transthyretin amyloid cardiomyopathy (ATTR‐CM) in patients with aortic stenosis (AS). read more here.

Keywords: amyloid cardiomyopathy; left atrial; transthyretin amyloid; aortic stenosis ... See more keywords

Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries

Sign Up to like & get
recommendations! Published in 2022 at "ESC Heart Failure"

DOI: 10.1002/ehf2.13961

Abstract: Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a progressive condition caused by deposition of transthyretin amyloid fibrils in the heart and is associated with poor quality of life and a shortened lifespan. This study aimed to describe… read more here.

Keywords: amyloid cardiomyopathy; transthyretin amyloid; prevalence; mortality patients ... See more keywords

SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin

Sign Up to like & get
recommendations! Published in 2022 at "ESC Heart Failure"

DOI: 10.1002/ehf2.14188

Abstract: Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) improve clinical outcomes in heart failure patients with reduced and preserved left ventricular ejection fraction (LVEF), but have not yet been investigated in transthyretin amyloid cardiomyopathy (ATTR‐CM). This study aimed… read more here.

Keywords: amyloid cardiomyopathy; inhibitor therapy; transthyretin amyloid; sglt2 inhibitor ... See more keywords

Health‐related quality of life among transthyretin amyloid cardiomyopathy patients

Sign Up to like & get
recommendations! Published in 2023 at "ESC Heart Failure"

DOI: 10.1002/ehf2.14350

Abstract: Transthyretin amyloid cardiomyopathy (ATTR CM) is a progressive and severe heart disease with physical and psychological implications. The Nordic PROACT study was conducted to investigate the health‐related quality of life (HRQoL) in ATTR CM patients. read more here.

Keywords: amyloid cardiomyopathy; transthyretin amyloid; quality life; related quality ... See more keywords

Prevalence of transthyretin amyloid cardiomyopathy in pacemaker patients

Sign Up to like & get
recommendations! Published in 2024 at "ESC Heart Failure"

DOI: 10.1002/ehf2.14645

Abstract: Transthyretin amyloid cardiomyopathy (ATTR‐CM) is characterized by increased wall thickness, diastolic dysfunction and progressive heart failure symptoms. The disease may infiltrate the conduction system leading to conduction disturbances requiring an implantation of permanent cardiac pacemaker… read more here.

Keywords: prevalence transthyretin; amyloid cardiomyopathy; pacemaker; transthyretin amyloid ... See more keywords

Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study

Sign Up to like & get
recommendations! Published in 2024 at "ESC Heart Failure"

DOI: 10.1002/ehf2.15147

Abstract: Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction. This… read more here.

Keywords: exercise limitations; limitations amyloid; amyloid cardiomyopathy; study ... See more keywords

Silencers versus stabilizers in amyloid cardiomyopathy. Are we asking the wrong questions?

Sign Up to like & get
recommendations! Published in 2025 at "European Journal of Heart Failure"

DOI: 10.1002/ejhf.3614

Abstract: Transthyretin (TTR) is a small tetrameric molecule with a half-life of 2–2.5days. 1 TTR cardiomyopathy is an increasingly recognized cause of progressive heart failure in the elderly and is associated with amyloid production derived from… read more here.

Keywords: amyloid cardiomyopathy; ttr; silencers versus; stabilizers amyloid ... See more keywords

Emerging, novel gene-modulating therapies for transthyretin amyloid cardiomyopathy

Sign Up to like & get
recommendations! Published in 2025 at "Heart Failure Reviews"

DOI: 10.1007/s10741-025-10502-5

Abstract: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, life-threatening disease caused by the pathological deposition of misfolded transthyretin (TTR) protein in the myocardium, leading to restrictive cardiomyopathy and heart failure. While TTR stabilizers such as tafamidis… read more here.

Keywords: modulating therapies; novel gene; amyloid cardiomyopathy; gene modulating ... See more keywords